Competitive GnRH receptor antagonist used in IVF.
Reference facts
- Also known as
- Antagon, Orgalutran
- Category
- GnRH & Reproductive
- Mechanism of action
- Competitive GnRH receptor antagonist used in IVF.
- Targets
- GnRH receptor (antagonist)
- Indications under research or approved
- IVF — prevention of premature LH surge
- Regulatory status (reference entry)
- FDA-approved (1999)
- Half-life
- ~13 hours
- Sequence notes
- Decapeptide GnRH antagonist with multiple D-amino acid substitutions.
- Molecular weight (Da)
- 1570
- Originator / sponsor
- Organon / Merck
- First reported
- 1992
Primary References
Explore research articles about Ganirelix
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.